Clinical Trial: The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional

Official Title: The Randomized, Controlled Clinical Trial of Apatinib Plus CIK as the Third Line Therapy for Lung Adenocarcinoma Patients With Wild-Type EGFR

Brief Summary: The purpose of this study is to evaluate the safety and efficacy of Apatinib combined with cytokine-induced killer cell (CIK) vs Apatinib alone as the third line therapy for advanced lung adenocarcinoma patients with wild-type EGFR

Detailed Summary: 400 patients with stage IIIB & IV lung adenocarcinoma who had received surgery and chemotherapy,will be randomly divided into group A（Apatinib plus CIK treatment ) or group B（Apatinib), and the randomize ratio will be 1:1. Patients in group A will receive 3 cycles of CIK treatment (every 1 year) and Apatinib (continuous).Patients in group B will receive only Apatinib (continuous) .
Sponsor: The First People's Hospital of Changzhou

Current Primary Outcome: Overall Survival (OS) [ Time Frame: 3 months ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Progression-Free-Survival (PFS) [ Time Frame: 3 months ]

Original Secondary Outcome: Same as current

Information By: The First People's Hospital of Changzhou

Dates:
Date Received: July 7, 2015
Date Started: July 2015
Date Completion: July 2033
Last Updated: February 4, 2016
Last Verified: February 2016